Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Quantum-Si incorporated (QSIAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: QSIAW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $
1 Year Target Price $
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.63% | Avg. Invested days 28 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.44B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.91 | 52 Weeks Range 0.05 - 2.23 | Updated Date 06/7/2025 |
52 Weeks Range 0.05 - 2.23 | Updated Date 06/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2982.42% |
Management Effectiveness
Return on Assets (TTM) -25.22% | Return on Equity (TTM) -40.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 146748948 |
Shares Outstanding - | Shares Floating 146748948 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Quantum-Si incorporated
Company Overview
History and Background
Quantum-Si incorporated was founded in 2013. It is a life sciences company focused on developing next-generation protein sequencing technology. They aim to revolutionize proteomics research and drug discovery.
Core Business Areas
- Next-Generation Protein Sequencing: Develops and commercializes the Platinum protein sequencing platform, consumables, and software.
Leadership and Structure
Dr. Jonathan Rothberg is the Founder and Chairman. The company has a traditional corporate structure with a CEO (Dr. Claudia Nicolau), CFO, and various VPs leading different departments.
Top Products and Market Share
Key Offerings
- Platinum Protein Sequencing Platform: A next-generation protein sequencing platform designed to analyze proteins directly. It currently does not have significant market share as it is still in early commercialization. Competitors include companies developing antibody sequencing methods (e.g., Twist Bioscience) and mass spectrometry-based proteomics (e.g., Thermo Fisher Scientific).
Market Dynamics
Industry Overview
The proteomics market is growing, driven by increasing demand for personalized medicine and drug discovery. Next-generation sequencing technologies are gaining traction.
Positioning
Quantum-Si is positioned as a disruptor in the proteomics market with its unique protein sequencing approach. Its competitive advantage lies in its label-free, single-molecule protein sequencing technology.
Total Addressable Market (TAM)
The total addressable market for proteomics is estimated to be in the billions of dollars annually. Quantum-Si is positioned to capture a share of this market by offering a novel protein sequencing platform.
Upturn SWOT Analysis
Strengths
- Novel protein sequencing technology
- Strong intellectual property portfolio
- Experienced leadership team
- Potential to disrupt proteomics market
Weaknesses
- Early stage commercialization
- Limited market presence
- Reliance on a single product platform
- High operating expenses
Opportunities
- Expanding applications of proteomics
- Strategic partnerships
- Technological advancements
- Growing demand for personalized medicine
Threats
- Competition from established players
- Technological obsolescence
- Regulatory hurdles
- Economic downturns
Competitors and Market Share
Key Competitors
- TMO
- ILMN
- PACB
- Twist Bioscience (No Ticker)
Competitive Landscape
Quantum-Si has a disruptive technology but faces strong competition from established companies with greater resources and market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been slow, reflecting the time it takes to develop novel instruments. Revenue growth is only just becoming apparent.
Future Projections: Analyst projections vary widely, but generally anticipate significant revenue growth as the company's platform gains adoption.
Recent Initiatives: Focus on product development and commercialization of the Platinum protein sequencing platform. Establish partnerships with key research institutions and pharmaceutical companies.
Summary
Quantum-Si is a company with innovative technology in the growing field of proteomics. However, the company is still early in its commercialization, and needs to focus on increasing sales and reducing its losses. The company faces competition from larger, more established players in proteomics. Overall, the technology is promising and the market is substantial but requires substantial investment and carries risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry publications
- Company website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data are estimates and may not be precise. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quantum-Si incorporated
Exchange NASDAQ | Headquaters Branford, CT, United States | ||
IPO Launch date 2021-06-11 | President, CEO & Director Mr. Jeffrey Alan Hawkins | ||
Sector Healthcare | Industry Medical Devices | Full time employees 149 | Website https://www.quantum-si.com |
Full time employees 149 | Website https://www.quantum-si.com | ||
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company offers Platinum NGPS instrument that provides single molecule amino acid level resolution with a streamlined workflow, including automated data analysis that accessible to researchers in all laboratory types; Platinum Pro NGPS instrument, a single molecule amino acid resolution, which provides an enhanced user interface, cloud or on instrument data analysis and an available pro mode; Library preparation kits to prepare protein sample for sequencing; Barcoding Kits to optimize the workflow and performance of technology; and Sequencing Kits contains the reagents and consumables used to perform NGPS on the Platinum or Platinum Pro instrument. It also provides Platinum Analysis Software, a cloud-based solution that automates data analysis workflows and provides a user-friendly interface and visualization of the sequencing results. Its products are used in antibody characterization, biomarker identification, protein identification, protein variants, protein barcoding, and post translational modification analysis applications. Quantum-Si incorporated was founded in 2013 is headquartered in Branford, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.